West Pharmaceutical Services (NYSE:WST) unveiled two new wearable injectors today from its SmartDose drug delivery platform as part of the annual PDA Universe of Pre-filled Syringes and Injection Devices meeting in Vienna, Austria.
West’s first-gen SmartDose device is a user-loaded injector designed to deliver high volumes of viscous drug products.
Its SmartDose Gen. II device is a wearable system that can handle injection volumes of up to 10 mL and accommodates both glass and Daikyo crystal zenith containers. The company’s third-gen device is a pre-loaded version, cutting back on the number of steps that patients have to take before administration.
“Advancements in drug development need to be paired with advances in drug delivery, such as last year’s FDA approval of the first combination product using our SmartDose drug delivery platform. Based on this technology, we are now excited to share our expanded portfolio of SmartDose wearable injectors,” West’s VP and chief technology officer Eric Resnick said in prepared remarks.
“As our customers continue to innovate and bring to market exciting new therapies to address important unmet medical needs, West is ready to help them with advancements in drug containment and delivery and technical expertise to guide them through the drug development and approval process.”
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.